Efficacy and safety of vericiguat added to GDMT regimen in the treatment of heart failure with reduced ejection fraction

ZHAO Xingyuan; CHEN Xiangyan; HU Nan; WANG Liying; XUE Hui; XIA Zongling

doi:10.6039/j.issn.1001-0408.2025.17.14

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of vericiguat added to GDMT regimen in the treatment of heart failure with reduced ejection fraction

更新时间：2025-09-29

- Efficacy and safety of vericiguat added to GDMT regimen in the treatment of heart failure with reduced ejection fraction
- ZHONGGUO YAOFANG Vol. 36, Issue 17, Pages: 2165-2169(2025)
- 作者机构：
  
  1.苏州大学附属第三医院药学部，江苏常州　213003
  2.常州市第一人民医院药学部，江苏常州　213003
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.17.14
  CLC： R972;R541.6
- Received：21 May 2025，
  
  Revised：2025-07-08，
  
  Accepted：29 July 2025，
  
  Published：15 September 2025
- 稿件说明：
移动端阅览
赵兴媛,陈祥燕,胡楠,等.GDMT方案加用维立西呱治疗射血分数降低型心力衰竭的有效性和安全性[J].中国药房,2025,36(17):2165-2169.

ZHAO Xingyuan,CHEN Xiangyan,HU Nan,et al.Efficacy and safety of vericiguat added to GDMT regimen in the treatment of heart failure with reduced ejection fraction[J].ZHONGGUO YAOFANG,2025,36(17):2165-2169.
赵兴媛,陈祥燕,胡楠,等.GDMT方案加用维立西呱治疗射血分数降低型心力衰竭的有效性和安全性[J].中国药房,2025,36(17):2165-2169. DOI： 10.6039/j.issn.1001-0408.2025.17.14.

ZHAO Xingyuan,CHEN Xiangyan,HU Nan,et al.Efficacy and safety of vericiguat added to GDMT regimen in the treatment of heart failure with reduced ejection fraction[J].ZHONGGUO YAOFANG,2025,36(17):2165-2169. DOI： 10.6039/j.issn.1001-0408.2025.17.14.

摘要

目的

评估指南指导的药物治疗（GDMT）方案加用维立西呱治疗射血分数降低型心力衰竭（HFrEF）的有效性和安全性。

方法

回顾性选择2023年1月至2024年5月在常州市第一人民医院接受规范化诊疗的HFrEF患者346例为研究对象，分为标准治疗组（

＝215）和维立西呱组（

＝131）。标准治疗组患者采用GDMT方案，维立西呱组患者采用GDMT加用维立西呱方案。采用倾向评分匹配（PSM）法平衡组间混杂因素，并评估两组患者有效性（包括结局指标和预后判断指标）和安全性（不良事件发生情况）。绘制主要和次要结局事件的Kaplan-Meier生存曲线，并通过单因素、多因素Cox回归分析筛选主要结局复合终点事件的影响因素。

结果

PSM后，标准治疗组和维立西呱组患者各100例，两组患者的基线资料比较，差异均无统计学意义（

＞0.05）。随访1年，标准治疗组和维立西呱组患者的主要结局复合终点事件累积发生率、因心力衰竭住院事件累积发生率、治疗前后的氨基末端脑利钠肽前体变化值差异均有统计学意义（

＜0.05）。两组患者的不良事件发生率比较，差异无统计学意义（

＞0.05）。多因素Cox回归分析结果显示，患者左室射血分数≤35%是1年内发生复合终点事件的危险因素[风险比（HR）＝2.090，95%置信区间（CI）（1.175，3.718），

＝0.012

]

，使用维立西呱是1年内发生复合终点事件的保护因素[HR＝0.505，95%CI（0.284，0.899），

＝0.020

]

。

结论

与GDMT方案比较，GDMT加用维立西呱方案可改善HFrEF患者的临床症状及预后，且安全性良好。

Abstract

OBJECTIVE

To evaluate the efficacy and safety of guideline-directed medical therapy （GDMT） combined with vericiguat in treating heart failure with reduced ejection fraction （HFrEF）.

METHODS

A retrospective study was conducted on 346 patients with HFrEF who received standardized diagnosis and treatment at the First People’s Hospital of Changzhou from January 2023 to May 2024. They were divided into standard treatment group （

＝215） and vericiguat group （

＝131）. Patients in the standard treatment group received GDMT， while patients in the vericiguat group received GDMT combined with vericiguat. Propensity score matching （PSM） was used to balance confounding factors between two groups， and the effectiveness （including outcome and prognostic indicators） and safety （occurrence of adverse events） of both groups were evaluated. Kaplan-Meier survival curves for primary and secondary outcome events were drawn， and the influential factors of primary outcome events were screened through univariate and multivariate Cox regression analysis.

RESULTS

After PSM， there were 100 patients in the standard treatment gro

up and 100 patients in the vericiguat group， and there was no statistically significant differences in baseline data between two groups （

＞0.05）. During a 1-year follow-up， there were statistically significant differences in the cumulative incidence of major outcome events between the standard treatment group and the vericiguat group， cumulative incidence of hospitalization events due to heart failure， changes in N-terminal pro-B-type natriuretic peptide levels before and after treatment between the standard treatment group and the vericiguat group （

＜0.05）. There was no statistically significant difference in the incidence of adverse events between the two groups （

＞0.05）. Multivariate Cox regression analysis results showed that left ventricular ejection fraction ≤35% was a risk factor for the occurrence of major outcome events within 1 year [hazard ratio （HR）＝2.090， 95% confidence interval （CI）： 1.175-3.718，

＝0.012

]

， while the use of vericiguat was a protective factor for the occurrence of major outcome events within 1 year （HR＝0.505， 95%CI： 0.284-0.899，

＝0.020）.

CONCLUSIONS

Compared with GDMT， GDMT combined with vericiguat can improve the clinical symptoms and prognosis of HFrEF patients， and has good safety.

关键词

Keywords

references

WANG H ， LI Y Y ， CHAI K ， et al . Mortality in patients admitted to hospital with heart failure in China：a nationwide Cardiovascular Association Database-Heart Failure Centre Registry cohort study [J ] . Lancet Glob Health ， 2024 ， 12 （ 4 ）： e611 - e622 .

URBICH M ， GLOBE G ， PANTIRI K ， et al . A systematic review of medical costs associated with heart failure in the USA：2014-2020 [J ] . Pharmacoeconomics ， 2020 ， 38 （ 11 ）： 1219 - 1236 .

SAVARESE G ， LINDBERG F ， CANNATA A ， et al . How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Fai- lure Association of the ESC [J ] . Eur J Heart Fail ， 2024 ， 26 （ 6 ）： 1278 - 1297 .

国家心血管病中心，国家心血管病专家委员会心力衰竭专业委员会，中国医师协会心力衰竭专业委员会，等 . 国家心力衰竭指南2023 [J ] . 中华心力衰竭和心肌病杂志， 2023 ， 7 （ 4 ）： 215 - 311 .

XIA J ， HUI N ， TIAN L ， et al . Development of vericiguat：the first soluble guanylate cyclase （sGC） stimulator launched for heart failure with reduced ejection fraction （HFrEF） [J ] . Biomed Pharmacother ， 2022 ， 149 ： 112894 .

ARMSTRONG P W ， PIESKE B ， ANSTROM K J ， et al . Vericiguat in patients with heart failure and reduced ejection fraction [J ] . N Engl J Med ， 2020 ， 382 （ 20 ）： 1883 - 1893 .

OH J ， LEE C J ， PARK J J ， et al . Real-world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction [J ] . ESC Heart Fail ， 2022 ， 9 （ 2 ）： 1492 - 1495 .

WANG Q ， WANG G C ， PENG J C ， et al . Characterizing vericiguat treatment in heart failure：a multicenter real-world study in China [J ] . Rev Cardiovasc Med ， 2024 ， 25 （ 12 ）： 427 .

ZHAO D ， ZHANG Y J ， YONG Y H ， et al . Vericiguat combined with “new quadruple” therapy enhances cardiac function and life quality in patients with heart failure：a single-center prospective study [J ] . Front Cardiovasc Med ， 2024 ， 11 ： 1476976 .

ZHAN Y G ， LI L ， ZHOU J ， et al . Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction：a prospective observational study [J ] . BMC Cardiovasc Disord ， 2025 ， 25 （ 1 ）： 83 .

TIAN J Y ， DONG M ， SUN X Q ， et al . Vericiguat in heart failure with reduced ejection fraction patients on guideline-directed medical therapy：insights from a 6-month real-world study [J ] . Int J Cardiol ， 2024 ， 417 ： 132524 .

中华医学会心血管病学分会，中国医师协会心血管内科医师分会，中国医师协会心力衰竭专业委员会，等 . 中国心力衰竭诊断和治疗指南2024 [J ] . 中华心血管病杂志， 2024 ， 52 （ 3 ）： 235 - 275 .

陈小东，周峻 . 芪苈强心胶囊与曲美他嗪在缺血性心肌病心力衰竭患者中的联合应用 [J ] . 中国实验方剂学杂志， 2015 ， 21 （ 19 ）： 171 - 175 .

U.S. Department of Health and Human Services . Common terminology criteria for adverse events （CTCAE） . Version 5.0[EB/OL ] . （ 2017-11-27 ） [ 2025-04-21 ] . https：//ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf .

彭嘉怡，高博，祝欢，等 . 社会经济地位对不同类型城市居民心理健康的影响路径分析 [J ] . 中国健康教育， 2022 ， 38 （ 10 ）： 882 - 887 .

MCDONAGH T A ， METRA M ， ADAMO M ， et al . 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [J ] . Eur Heart J ， 2021 ， 42 （ 36 ）： 3599 - 3726 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Dapagliflozin on acute kidney injury and prognosis in patients with diabetes mellitus type 2 and acute coronary syndrome after percutaneous coronary intervention

Statistical analysis of adverse drug reactions of Trastuzumab for injection from 2018 to 2023 in Beijing

Associations of MTRR gene polymorphism and methotrexate plasma concentration and adverse drug reaction in children with intracranial tumors

Practice and analysis of clinical pharmacist participating in the treatment of a case of acanthoma caused by navulizumab

曲妥珠单抗联合术前辅助化疗用于Her-2阳性乳腺癌的临床观察

Related Author

ZHANG Peng

HAO Huifang

YANG Shicheng

LI Qing

ZHAI Xiufeng

ZHANG Wensi

BAI Yu

WANG Xiaoyang

Related Institution

Dept. of Nephrology， Tianjin TEDA Hospital

Tianjin Rehabilitation and Recuperation Center， Joint Logistics Support Force

Dept. of Cardiology， Tianjin Chest Hospital

Dept. of Pharmacy， Beijing Cancer Hospital & Beijing Institute for Cancer Research/Key Laboratory of Carcinogenesis and Translational Research， Ministry of Education

Beijing Drug Adverse Event Monitoring Center

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰